BiVictriX Therapeutics (LON:BVX) Shares Down 3.9%

BiVictriX Therapeutics Plc (LON:BVX)’s stock price traded down 3.9% on Wednesday . The stock traded as low as GBX 12.01 ($0.15) and last traded at GBX 12.01 ($0.15). 1,735 shares traded hands during mid-day trading, a decline of 96% from the average session volume of 45,693 shares. The stock had previously closed at GBX 12.50 ($0.16).

BiVictriX Therapeutics Stock Down 3.9 %

The company has a debt-to-equity ratio of 14.51, a current ratio of 6.85 and a quick ratio of 7.49. The firm’s 50 day moving average is GBX 11.61 and its two-hundred day moving average is GBX 11.38. The firm has a market capitalization of £9.91 million, a P/E ratio of -300.25 and a beta of -0.61.

BiVictriX Therapeutics Company Profile

BiVictriX Therapeutics Plc, a biotechnology company, engages in the development of cancer therapies in the United Kingdom. The company develops Bi-Cygni therapeutics, which are selective for cancer types. Its lead program is BVX001, focuses on acute myeloid leukaemia, as well as develops BVX002 and BVX003 for various blood cancers and solid tumours.